Novo Nordisk Entered into a Research and Development Collaboration with Life Edit Therapeutics to Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases
Shots:
- Life Edit will receive an up front, ~$335M in development, regulatory, and commercial milestones for each of the first 2 development programs, ~$250M for each of the 5 development programs along with royalties on future net sales of therapeutic products
- Novo Nordisk will be responsible for all R&D costs & has also made an equity investment in ElevateBio as part of its $401M series D financing round while Life Edit gets an option to a global profit share on 1 program
- Novo Nordisk will use Life Edit’s suite of gene editing technologies to accurately edit the genome with a focus on improving base editing capabilities & developing therapies for rare genetic disorders & cardiometabolic diseases
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Reports P-IIIa Trial (OASIS 1) Results of Semaglutide for the Treatment of Obesity or Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
